{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:33:40Z","timestamp":1787751220180,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R34 AA026032"],"award-info":[{"award-number":["R34 AA026032"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["RO1 DA034261"],"award-info":[{"award-number":["RO1 DA034261"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["NCT01751789"],"award-info":[{"award-number":["NCT01751789"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jsat.2019.12.007","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T03:18:19Z","timestamp":1576207099000},"page":"37-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification"],"prefix":"10.1016","volume":"110","author":[{"given":"Michael D.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon R.","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah T.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jsat.2019.12.007_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: A survey among substance misusers","volume":"20","author":"Baird","year":"2014","journal-title":"European Addiction Research"},{"issue":"7","key":"10.1016\/j.jsat.2019.12.007_bb0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1081\/CLT-120016965","article-title":"Gabapentin withdrawal presenting as status epilepticus","volume":"40","author":"Barrueto","year":"2002","journal-title":"Journal of Toxicology. Clinical Toxicology"},{"issue":"4","key":"10.1016\/j.jsat.2019.12.007_bb0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11126-016-9421-7","article-title":"Abuse of gabapentin is associated with opioid addiction","volume":"87","author":"Bastiaens","year":"2016","journal-title":"The Psychiatric Quarterly"},{"issue":"9","key":"10.1016\/j.jsat.2019.12.007_bb0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/pds.4230","article-title":"Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: Diversion rates and qualitative research findings","volume":"26","author":"Buttram","year":"2017","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.jsat.2019.12.007_bb0025","first-page":"1","article-title":"\u201cThat\u2019s what we call the cocktail\u201d: Non-opioid medication and supplement misuse among opioid users","author":"Chatterjee","year":"2019","journal-title":"Substance Abuse"},{"issue":"36","key":"10.1016\/j.jsat.2019.12.007_bb0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults \u2014 United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"issue":"4","key":"10.1016\/j.jsat.2019.12.007_bb0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of Pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.jsat.2019.12.007_bb0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3821\/145.6.cpj280","article-title":"Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists","volume":"145","author":"Fukada","year":"2012","journal-title":"Can Pharm J (Ott)"},{"issue":"10","key":"10.1016\/j.jsat.2019.12.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.jsat.2019.12.007_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"Hakkinen","year":"2014","journal-title":"Forensic Science International"},{"key":"10.1016\/j.jsat.2019.12.007_bb0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2014.08.030","article-title":"Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats","volume":"742","author":"Hasanein","year":"2014","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2019.12.007_bb0060","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.2105\/AJPH.2013.301709","article-title":"Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States","volume":"104","author":"Keyes","year":"2014","journal-title":"American Journal of Public Health"},{"issue":"1","key":"10.1016\/j.jsat.2019.12.007_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1081\/CLT-120018265","article-title":"Characterization of gabapentin overdose using a poison center case series","volume":"41","author":"Klein-Schwartz","year":"2003","journal-title":"Journal of Toxicology. Clinical Toxicology"},{"issue":"4","key":"10.1016\/j.jsat.2019.12.007_bb0070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.pra.0000358318.73684.df","article-title":"Gabapentin-induced delirium and dependence","volume":"15","author":"Kruszewski","year":"2009","journal-title":"Journal of Psychiatric Practice"},{"issue":"9","key":"10.1016\/j.jsat.2019.12.007_bb0075","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/add.13843","article-title":"Risk to heroin users of polydrug use of pregabalin or gabapentin","volume":"112","author":"Lyndon","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2019.12.007_bb0080","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","volume":"4","author":"Moore","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2019.12.007_bb0085","article-title":"Investogating gabapentin as a drug of abuse: Associations between gabapentin prescribing, substance use disorders and opioid-related poisonings","author":"Pauly","year":"2017"},{"key":"10.1016\/j.jsat.2019.12.007_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: The case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Healthc Policy"},{"issue":"4","key":"10.1016\/j.jsat.2019.12.007_bb0095","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/phar.2096","article-title":"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population","volume":"38","author":"Peckham","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jsat.2019.12.007_bb0100","article-title":"Gabapentin for off-label use: Evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst Abuse"},{"issue":"2","key":"10.1016\/j.jsat.2019.12.007_bb0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-017-0595-1","article-title":"All-cause and drug-related medical events associated with overuse of gabapentin and\/or opioid medications: A retrospective cohort analysis of a commercially insured US population","volume":"41","author":"Peckham","year":"2018","journal-title":"Drug Safety"},{"issue":"8","key":"10.1016\/j.jsat.2019.12.007_bb0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jat\/33.8.545","article-title":"Prevalence of gabapentin in impaired driving cases in Washington state in 2003-2007","volume":"33","author":"Peterson","year":"2009","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/j.jsat.2019.12.007_bb0115","author":"Quintiles IMS Institute"},{"issue":"6","key":"10.1016\/j.jsat.2019.12.007_bb0120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2019.12.007_bb0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drugalcdep.2018.01.018","article-title":"Prevalence of gabapentin in drug overdose postmortem toxicology testing results","volume":"186","author":"Slavova","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1016\/j.jsat.2019.12.007_bb0130","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: A systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jsat.2019.12.007_bb0135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","article-title":"Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky","volume":"172","author":"Smith","year":"2015","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2019.12.007_bb0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fphar.2015.00104","article-title":"Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin","volume":"6","author":"Stoicea","year":"2015","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1016\/j.jsat.2019.12.007_bb0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMp1806486","article-title":"The FDA and the next wave of drug abuse - proactive pharmacovigilance","volume":"379","author":"Throckmorton","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.jsat.2019.12.007_bb0150","doi-asserted-by":"crossref","first-page":"727","DOI":"10.7326\/M18-2175","article-title":"Combined gabapentinoid and opioid use: The consequences of shifting prescribing trends","volume":"169","author":"Throckmorton","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2019.12.007_bb0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2006-958522","article-title":"Abuse, dependency and withdrawal with gabapentin: A first case report","volume":"40","author":"Victorri-Vigneau","year":"2007","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.jsat.2019.12.007_bb0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ajad.12159","article-title":"Prescription medication misuse among opioid dependent patients seeking inpatient detoxification","volume":"24","author":"Wilens","year":"2015","journal-title":"The American Journal on Addictions"},{"issue":"3","key":"10.1016\/j.jsat.2019.12.007_bb0165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13181-014-0384-5","article-title":"Clinical outcomes in newer anticonvulsant overdose: A poison center observational study","volume":"10","author":"Wills","year":"2014","journal-title":"Journal of Medical Toxicology"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219304489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219304489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:00:11Z","timestamp":1778540411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219304489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"alternative-id":["S0740547219304489"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.12.007","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}